| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2002;74:1648-1652
© 2002 The Society of Thoracic Surgeons
a Department of Cardiothoracic Surgery, Cork University Hospital, Wilton, Cork, Ireland
b Department of Academic Surgery, Cork University Hospital and University College Cork, Wilton, Cork, Ireland
c Department of Surgery, Cork University Hospital and University College Cork, Wilton, Cork, Republic of Ireland
Accepted for publication June 28, 2002.
* Address reprint requests to Dr Redmond, Department of Academic Surgery, Cork University Hospital, Wilton, Cork, Republic of Ireland
e-mail: redmondhp{at}shb.ie
BACKGROUND: Human lung cancer is a major cause of death worldwide with few known effective therapeutic modalities. The isoenzyme cyclooxygenase 2 (COX-2) is an inducible inflammatory enzyme with increased activity evidenced in lung carcinoma. The objective was to determine the effect of a selective COX-2 inhibitor on proliferation and apoptosis rates in the Lewis lung (3LL) tumor cell line in vitro.
METHODS: First, 1 x 104 3LL cells were plated in a 96-well plate. Cells were incubated for 24 hours with either a control or increasing doses of rofecoxib (0.1 mmol/L, 0.25 mmol/L, 0.5 mmol/L, 1.0 mmol/L, and 2.5 mmol/L) in complete Dulbecco’s Modified Eagle’s Medium culture medium. Cell proliferation was measured using BrdU enzyme-linked immunosorbent assay. Next, 1 x 106 3LL cells were similarly treated. Cells were permeabilized, immunostained with propidium iodide and apoptotic rates were measured using flow cytometry. Then, 5 x 104 cells were plated on a 24-well plate. Cells were incubated for 24 hours with either control or increasing doses of rofecoxib (0.1 mmol/L, 0.25 mmol/L, 0.5 mmol/L, 1.0 mmol/L, and 2.5 mmol/L) in complete culture medium. Supernatant was collected and lactate dehydrogenase was measured for cell necrosis using a cytotoxicity detection kit.
RESULTS: The selective COX-2 inhibitor rofecoxib resulted in a dose-dependent increase in apoptosis and dose and time-dependent growth inhibition in cell proliferation. However, rofecoxib did not cause cell necrosis.
CONCLUSIONS: There was a significant decrease in proliferation and increase in apoptosis of 3LL tumor cells when treated with the highly selective COX-2 inhibitor rofecoxib. COX-2 inhibitors may have a potential role to play in the treatment of lung carcinoma.
This article has been cited by other articles:
|
|
 |
|
  M. Alam, J. H. Wang, J. C. Coffey, S. S. Qadri, A. O'Donnell, T. Aherne, and H. P. Redmond Characterization of the Effects of Cyclooxygenase-2 Inhibition in the Regulation of Apoptosis in Human Small and Non Small Cell Lung Cancer Cell Lines Ann. Surg. Oncol., September 1, 2007; 14(9): 2678 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Zatelli, A. Luchin, D. Piccin, F. Tagliati, A. Bottoni, C. Vignali, M. Bondanelli, and E. C. degli Uberti Cyclooxygenase-2 Inhibitors Reverse Chemoresistance Phenotype in Medullary Thyroid Carcinoma by a Permeability Glycoprotein-Mediated Mechanism J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5754 - 5760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S.A. Qadri, J.-H. Wang, J. C. Coffey, M. Alam, A. O'Donnell, T. Aherne, and H. P. Redmond Surgically Induced Accelerated Local and Distant Tumor Growth is Significantly Attenuated by Selective COX-2 Inhibition Ann. Thorac. Surg., March 1, 2005; 79(3): 990 - 995. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
